What Is NAD+? What It Does in Human Cells

What is NAD+?

NAD+ is nicotinamide adenine dinucleotide, a coenzyme found in human cells. It helps transfer electrons in energy metabolism and also supplies a substrate for several signaling and repair enzymes. NAD+ is not a peptide, hormone, or treatment. Cells continually make, use, and regenerate it, and its effects depend on tissue, compartment, metabolic state, and the balance between synthesis and consumption.

The basic definition: a coenzyme, not a peptide

The name nicotinamide adenine dinucleotide describes a small molecule built from an adenine-containing portion and a nicotinamide-containing portion. In biochemistry, a coenzyme is a helper molecule that works with an enzyme. NAD+ is therefore not an enzyme that catalyzes reactions by itself. It is a reusable participant that accepts or donates electrons as particular reactions require. The plus sign identifies its oxidized form.

This distinction matters because NAD+ is often discussed beside peptides, supplements, and “longevity” interventions. A peptide is a chain of amino acids, such as the mitochondrial-derived peptide MOTS-c. NAD+ is not an amino-acid chain and is not interchangeable with MOTS-c. Their biology can appear in the same metabolism conversation, but one is a small-molecule coenzyme and the other is a peptide research subject. The NAD+ versus MOTS-c comparison keeps those categories separate.

NAD+ is also not a single “energy molecule” with one job. Its chemistry allows cells to connect reactions that release electrons with reactions that need them. The same cellular NAD pool can be used in redox reactions, while other NAD molecules may be consumed by enzymes involved in protein deacylation or DNA-damage signaling. Asking what NAD+ does consequently requires asking which reaction, cell, tissue, and subcellular compartment are being described.[1]

NAD+ and NADH: the redox cycle

The clearest role of NAD+ is redox chemistry. NAD+ can accept electrons, along with a hydrogen equivalent, and become NADH. NADH can later give those electrons away and return to NAD+. This reversible NAD+/NADH pair helps maintain the flow of electrons through metabolic pathways. “Oxidized” and “reduced” describe the electron state; they are not names for two unrelated supplements or two separate nutrients.

During glycolysis, reactions in the cytosol reduce NAD+ to NADH. Glycolysis cannot continue indefinitely unless enough NAD+ is regenerated, so cells need routes that return NADH to the oxidized form. The tricarboxylic acid cycle, often called the TCA cycle, also produces NADH when carbon fuels are processed. These reactions show why the ratio and movement of NAD+ and NADH can matter as much as the amount of either one in isolation.

In aerobic metabolism, NADH delivers electrons to the mitochondrial electron transport chain through systems that transfer reducing equivalents into the appropriate mitochondrial setting. Electron flow helps establish the gradient used by oxidative phosphorylation to make ATP. The careful wording is important: NADH contributes electrons to this process, while NAD+ is the oxidized coenzyme that must be regenerated for upstream reactions to continue. NAD+ itself is not a tiny battery that directly makes ATP, and increasing a measured NAD-related value does not automatically demonstrate greater ATP production.[1][2]

Redox chemistry is also constrained by transport and compartment boundaries. Cytosolic and mitochondrial reactions are related, but NAD(H) pools are not one perfectly mixed tank. Cells use shuttles and compartment-specific reactions to coordinate reducing equivalents. A result measured in one pool may not describe every other pool, which is one reason a whole-blood measurement cannot simply be translated into a complete map of cellular energy metabolism.

One name, different cellular pools

Mitochondria, cytosol, nucleus, and other cellular locations have distinct chemical environments and demands. NAD+ participates in reactions in more than one of these compartments, but access, regeneration, and consumption are compartment-dependent. A cell can therefore experience different NAD(H) conditions in its mitochondria and cytosol even when a single assay reports “NAD+” for a sample. Tissue composition and sample handling add further sources of variation.[1]

Blood is a useful and accessible sample, but blood NAD+ is not a universal readout of every tissue’s NAD+ pool. Circulating cells and plasma-related measurements do not necessarily represent skeletal muscle, liver, brain, or a particular mitochondrial compartment. Human studies that report a biochemical change in blood or a sampled tissue should be described as measuring that sample, not as proving that all cells throughout the body changed in the same way.

NAD+ is also consumed by signaling and repair enzymes

NAD+ is not used only as an electron carrier. Some enzymes consume NAD+ while transferring chemical groups or otherwise changing target proteins. Sirtuins are NAD+-dependent enzymes that remove acyl groups from proteins, including acetyl groups in some reactions. This connects NAD availability with regulation of proteins involved in metabolism and cellular responses. It does not make NAD+ a “longevity switch,” and a molecular reaction is not the same thing as a longer or healthier human life.[1]

Poly(ADP-ribose) polymerases, usually called PARPs, also consume NAD+ while carrying out ADP-ribosylation reactions. These enzymes participate in responses to DNA damage and other cellular signals. “PARP activity” is not one uniform process: PARP family members have different roles and catalytic behavior, so a general statement that “PARPs repair everything” or that blocking all PARP activity would be beneficial is not justified. The relevant point for NAD biology is that repair-related consumption can draw on the same broader supply that redox and other reactions depend on.[1][2]

CD38 is another NAD-consuming enzyme system discussed in NAD metabolism and aging research. Its presence illustrates the balance problem: NAD levels reflect both how cells synthesize or salvage the molecule and how quickly enzymes consume it. Describing one consumer as universally harmful, or one increase in NAD as universally beneficial, skips the context that determines what a cell is doing and what it needs.[1]

How cells make NAD+: synthesis, salvage, and consumption

Human cells can maintain NAD+ through more than one route. De novo synthesis starts from dietary tryptophan through a multistep pathway. Other routes use precursors related to vitamin B3 chemistry. The salvage pathway recycles nicotinamide, a product released when NAD+-consuming enzymes have used NAD+. These routes are not interchangeable in every tissue or condition, and their relative contribution can vary with cell type, nutrient state, and metabolic demand.[1][2]

The useful mental model is a balance sheet rather than a tank that only needs filling. Production and salvage add to the available pool; redox reactions cycle NAD+ and NADH; sirtuins, PARPs, CD38, and other reactions consume NAD+ or generate products that must be handled. A measured low or high value can therefore have more than one explanation. The right biological question is not simply “how do I raise NAD+?” but what changed the pool, where it changed, and what downstream process followed.

Nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN, are discussed as precursors in this field. They are not NAD+ itself. A precursor may enter a pathway that contributes to NAD-related chemistry, but precursor exposure, blood measurements, intracellular target engagement, and a clinically meaningful outcome are different claims. Evidence for one cannot be silently substituted for evidence for the others.

What changes with age?

Age-associated NAD+ declines have been reported in multiple animal models and some human tissues, but there is no single universal percentage decline that applies to every person, tissue, species, or assay. Findings vary across experimental models and human studies, with differences in age range, tissue sampled, health status, measurement method, and whether researchers measured NAD+, related metabolites, or an NAD+/NADH relationship. A simple “NAD falls by X percent” statement hides those differences.[1][4]

The more defensible conclusion is that NAD metabolism can change with aging and disease-related contexts, while the size, direction, and importance of that change are not universal. Animal models can help identify mechanisms and test hypotheses. They do not establish that the same pattern occurs in every human tissue or that correcting a biochemical measurement will produce a human anti-aging benefit. Even within humans, an age-associated association is not proof that NAD change is the sole cause of a symptom or disease.

Human evidence and preclinical evidence are different

Preclinical evidence includes cell and animal experiments. Those studies can clarify pathways, show how an intervention behaves in a controlled model, and identify questions for human research. They cannot by themselves establish a benefit for people. Human evidence can include measurements in people or randomized intervention studies, but those categories also differ: measuring a metabolite is not the same as demonstrating that changing it improves a clinical outcome.

The human NR literature illustrates why careful wording matters. A review of 25 human NR articles found some endpoint-specific signals and biochemical changes, alongside few clinically relevant effects overall; it did not support a universal wellness promise or a claim that every result was negative.[3] This is a mixed evidence picture, not a reason to force every study into either “NAD works” or “NAD does nothing.”

A later systematic review covering studies published from January 2010 through October 2025 included 33 human and 80 rodent studies. It reported relatively consistent NAD-related biochemical changes in circulation or sampled cells with NR or NMN, but heterogeneous outcomes that were often null or endpoint-specific. The review described short-term studies as generally well tolerated while emphasizing that this does not establish long-term safety or prove clinical anti-aging or wellness efficacy.[4]

The remaining uncertainty is specific. Researchers still need to know which people and tissues matter, whether a blood change reflects an intracellular change, which outcomes are meaningful, and what longer-term safety looks like. Preclinical enthusiasm can motivate those studies, but it cannot answer them in advance.[2]

Five questions readers often ask

Read the evidence in context

The central question is whether a measured NAD+ change occurs in the relevant tissue and leads to a meaningful human outcome. For a broader comparison of the two molecules, explore NAD+ vs MOTS-c, with the paperback available on Amazon.

Related reading: NAD+ decline with age · NAD+ vs MOTS-c · What is MOTS-c? · all articles